Overdiagnosis of Breast Cancer
Deanna J. Attai, MD, surgeon, president, Center For Breast Care, Burbank, CA, discusses the overdiagnosis of breast cancer.
Deanna J. Attai, MD, surgeon, president, Center For Breast Care, Burbank, CA, discusses the overdiagnosis of breast cancer.
The presentation at the 2013 Breast Cancer Symposium was particularly good, Attai says, because it looked at breast cancer diagnosis from the perspective of a pathologist, radiologist, and surgeon.
Clinical Pearls
Because breast cancer is a complicated disease, pathologists sometimes have a hard time determining between high-risk lesions and low-grade cancer, Attai says. Instead of just issuing a blanket statement that breast cancer is being overdiagnosed and overtreated, the oncology community needs to dig deeper into the definition and identification of the disease in order to individualize treatment.
- Pathologists sometimes have difficulty determining between high-risk lesions and low-grade cancer
- There is a need to dig deeper into the definition and identification of breast cancer
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
December 20th 2024During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed considerations affecting first- and second-line treatment of metastatic HER2-positive breast cancer in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
